BioCryst Pharmaceuticals, Inc.
BCRX

$1.51 B
Marketcap
$7.30
Share price
Country
$0.20
Change (1 day)
$8.88
Year High
$4.03
Year Low
Categories

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

marketcap

Revenue of BioCryst Pharmaceuticals, Inc. (BCRX)

Revenue in 2023 (TTM): $331.41 M

According to BioCryst Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $331.41 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of BioCryst Pharmaceuticals, Inc.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $331.41 M $326.75 M $-116,335,000 $-226,229,000 $-226,539,000
2022 $270.83 M $264.23 M $-143,854,000 $-244,384,000 $-247,117,000
2021 $157.17 M $149.91 M $-121,738,000 $-181,809,000 $-184,062,000
2020 $17.81 M $16.14 M $-167,565,000 $-182,814,000 $-196,567,000
2019 $48.84 M $44.73 M $-96,281,000 $-108,897,000 $-120,065,000
2018 $20.65 M $20.18 M $-90,365,000 $-101,252,000 $-101,252,000
2017 $25.19 M $23.48 M $-56,513,000 $-65,782,000 $-65,782,000
2016 $26.35 M $23.65 M $-48,174,000 $-55,144,000 $-55,144,000
2015 $48.26 M $46.36 M $-37,639,000 $-43,019,000 $-43,019,000
2014 $13.61 M $13.49 M $-40,014,000 $-45,189,000 $-45,189,000
2013 $17.33 M $17.23 M $-25,026,000 $-30,108,000 $-30,108,000
2012 $26.29 M $26.16 M $-33,787,000 $-39,081,000 $-39,081,000
2011 $19.64 M $19.64 M $-52,288,000 $-56,948,000 $-56,948,000
2010 $63.5 M $63.42 M $-31,585,814 $-33,853,183,000 $-32,733,000
2009 $74.59 M $70.05 M $-11,839,021 $-13,452,000 $-13,452,000
2008 $56.56 M $56.56 M $-23,105,692 $-24,732,000 $-24,731,570
2007 $71.24 M $71.24 M $-27,685,811 $-29,055,000 $-29,055,524
2006 $6.21 M $6.21 M $-42,796,658 $-26,098,768,000 $-43,617,853
2005 $151.87 K $151.87 K $-25,234,201 $-26,098,768,000 $-26,098,768
2004 $336.9 K $336.9 K $-20,134,672 $-21,104,121,000 $-21,104,121
2003 $1.63 M $1.63 M $-12,578,819 $-12,700,083,000 $-12,700,000
2002 $1.77 M $1.77 M $-17,456,577 $-16,928,671,000 $-16,928,671
2001 $11.16 M $11.16 M $-3,936,077 $-4,985,976,000 $-4,985,976
2000 $3.32 M $3.32 M $-9,162,800 $-11,577,842,000 $-11,577,842
1999 $2.5 M $3 M $-7,600,000 $-6,900,000 $-5,300,000
1998 $6.4 M $6.9 M $-5,500,000 $-4,700,000 $-4,800,000
1997 $1000 K $1.6 M $-11,700,000 $-10,600,000 $-10,600,000
1996 $2.7 M $-4,400,000 $-8,200,000 $ $-7,700,000
1995 $200 K $-6,300,000 $-8,500,000 $-8,400,000 $-8,600,000
1994 $700 K $-4,300,000 $-6,200,000 $ $-6,900,000